Get the Stockscreener App
9.55
4.60%
-0.46
Pharming Group N V Adr stock is traded at $9.55, with a volume of 21,295.
It is down -4.60% in the last 24 hours and up +4.95% over the past month.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.
See More
Previous Close:
$10.01
Open:
$9.88
24h Volume:
21,295
Relative Volume:
3.19
Market Cap:
$647.83M
Revenue:
$277.56M
Net Income/Loss:
$-13.33M
P/E Ratio:
-50.26
EPS:
-0.19
Net Cash Flow:
$-6.54M
1W Performance:
-3.83%
1M Performance:
+4.95%
6M Performance:
+12.22%
1Y Performance:
-21.27%
1-Day Range:
$9.29
$9.99
1-Week Range:
$9.29
$10.01
52-Week Range:
$6.65
$13.20
Pharming Group N V Adr Stock (PHAR) Company Profile
Compare PHAR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHAR
Pharming Group N V Adr
|
9.55 | 647.83M | 277.56M | -13.33M | -6.54M | -0.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Pharming Group N V Adr Stock (PHAR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-24 | Initiated | Jefferies | Buy |
Pharming Group N V Adr Stock (PHAR) Latest News
Pharming Group (OTCMKTS:PHGUF) Shares Cross Above 50 Day Moving Average – Time to Sell? - Defense World
Pharming Group stock gains on KL1333’s blockbuster potential, says RBC - Investing.com India
Pharming announces public cash offer to the shareholders of Abliva AB - GlobeNewswire Inc.
H.C. Wainwright reiterates Buy on Pharming stock, pediatric trial shows safety and tolerability - Investing.com India
Jefferies initiates Pharming Group shares with Buy on revenue growth - Investing.com India
Oppenheimer cuts Pharming Group stock target, Outperform on Q3 results - Investing.com India
Earnings call: Pharming Group NV reports growth amid CEO transition - Investing.com
Earnings call: Pharming Group NV sees robust growth in Q3, CEO to step down - Investing.com
October 2024's Promising Penny Stocks to Watch - Yahoo Finance
Novavax (NVAX) Moves 19.2% Higher: Will This Strength Last? - Yahoo Finance
Earnings call: Pharming Group reports robust growth and pipeline expansion - Investing.com India
Pharming Group stock hits 52-week low at $6.9 amid challenges - Investing.com
Pharming (PHAR) Rare Disease Drug Joenja Gets FDA Nod, Stock Up - Nasdaq
Can Pharming Group N.V. Sponsored ADR (PHAR) Run Higher on Rising Earnings Estimates? - Zacks Investment Research
PHARM Stock Price and Chart — EURONEXT:PHARM - TradingView
Pharming Group N V Adr Stock (PHAR) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):